Posted by Michael Wonder on 12 Jan 2024
Health Canada grants priority review status of ViiV Healthcare's new drug submission for cabotegravir long-acting injectable and tablets for prevention of HIV
10 January 2024 - Application is supported by data from the pivotal Phase 2b/3 studies evaluating safety and efficacy of long-acting cabotegravir for pre-exposure prophylaxis in men who have sex with men, transgender women, and cisgender women at increased risk of HIV acquisition.
ViiV Healthcare has filed a new drug submission to Health Canada for investigational, cabotegravir long-acting injectable and tablets for pre-exposure prophylaxis. The submission is being reviewed under the priority review policy.
